280 related articles for article (PubMed ID: 32927129)
41. Strategic analyses to identify key structural features of antiviral/antimalarial compounds for their binding interactions with 3CLpro, PLpro and RdRp of SARS-CoV-2:
Dhote AM; Patil VR; Lokwani DK; Amnerkar ND; Ugale VG; Charbe NB; Bhongade BA; Khadse SC
J Biomol Struct Dyn; 2022; 40(22):11914-11931. PubMed ID: 34431452
[TBL] [Abstract][Full Text] [Related]
42. In Silico Screening of the DrugBank Database to Search for Possible Drugs against SARS-CoV-2.
Cuesta SA; Mora JR; Márquez EA
Molecules; 2021 Feb; 26(4):. PubMed ID: 33669720
[TBL] [Abstract][Full Text] [Related]
43. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.
Li Y; Chu F; Li P; Johnson N; Li T; Wang Y; An R; Wu D; Chen J; Su Z; Gu X; Ding X
J Ethnopharmacol; 2021 May; 271():113854. PubMed ID: 33513419
[TBL] [Abstract][Full Text] [Related]
44. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome.
Sardanelli AM; Isgrò C; Palese LL
Molecules; 2021 Mar; 26(5):. PubMed ID: 33807773
[TBL] [Abstract][Full Text] [Related]
45. Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2.
Yassine R; Makrem M; Farhat F
Biomed Res Int; 2021; 2021():6696012. PubMed ID: 34124259
[TBL] [Abstract][Full Text] [Related]
46. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
[TBL] [Abstract][Full Text] [Related]
47. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM
J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513
[TBL] [Abstract][Full Text] [Related]
48. Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations.
Nguyen HL; Thai NQ; Truong DT; Li MS
J Phys Chem B; 2020 Dec; 124(50):11337-11348. PubMed ID: 33264025
[TBL] [Abstract][Full Text] [Related]
49. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
[TBL] [Abstract][Full Text] [Related]
51. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
[TBL] [Abstract][Full Text] [Related]
52. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
Vardhan S; Sahoo SK
Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
[TBL] [Abstract][Full Text] [Related]
53. Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review.
Kaul R; Paul P; Kumar S; Büsselberg D; Dwivedi VD; Chaari A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681727
[TBL] [Abstract][Full Text] [Related]
54. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.
Konno S; Kobayashi K; Senda M; Funai Y; Seki Y; Tamai I; Schäkel L; Sakata K; Pillaiyar T; Taguchi A; Taniguchi A; Gütschow M; Müller CE; Takeuchi K; Hirohama M; Kawaguchi A; Kojima M; Senda T; Shirasaka Y; Kamitani W; Hayashi Y
J Med Chem; 2022 Feb; 65(4):2926-2939. PubMed ID: 34313428
[TBL] [Abstract][Full Text] [Related]
55. Tomatidine and Patchouli Alcohol as Inhibitors of SARS-CoV-2 Enzymes (3CLpro, PLpro and NSP15) by Molecular Docking and Molecular Dynamics Simulations.
Zrieq R; Ahmad I; Snoussi M; Noumi E; Iriti M; Algahtani FD; Patel H; Saeed M; Tasleem M; Sulaiman S; Aouadi K; Kadri A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639036
[TBL] [Abstract][Full Text] [Related]
56. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
[TBL] [Abstract][Full Text] [Related]
57. In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling.
Mosayebnia M; Hajiagha Bozorgi A; Rezaeianpour M; Kobarfard F
J Biomol Struct Dyn; 2022 Sep; 40(14):6569-6586. PubMed ID: 33599180
[TBL] [Abstract][Full Text] [Related]
58. Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2.
Wang YT; Long XY; Ding X; Fan SR; Cai JY; Yang BJ; Zhang XF; Luo RH; Yang L; Ruan T; Ren J; Jing CX; Zheng YT; Hao XJ; Chen DZ
Eur J Med Chem; 2022 Jan; 227():113966. PubMed ID: 34749200
[TBL] [Abstract][Full Text] [Related]
59. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
[TBL] [Abstract][Full Text] [Related]
60. Allergen fragrance molecules: a potential relief for COVID-19.
Aydın AD; Altınel F; Erdoğmuş H; Son ÇD
BMC Complement Med Ther; 2021 Jan; 21(1):41. PubMed ID: 33478471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
